Clinical Trials on Prostatic Hyperplasia in New Zealand

Total 1405 results

Bristol-Myers Squibb

Completed

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Metastatic Prostate Cancer

United States
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

Prostate Cancer | Hormone Refractory Prostate Cancer

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); AbbVie; Rutgers Cancer Institute of New Jersey

Terminated

Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

Prostate Cancer

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Terminated

Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Prostate Cancer

United States
Xanthus Pharmaceuticals, Inc.

Completed

Study of Individualized Amonafide to Treat Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
Capcure

Completed

Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer

Cancer | Prostate

United States
National Cancer Institute (NCI)

Completed

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer

Prostate Cancer

United States
Weill Medical College of Cornell University
Cancer Research & Treatment Fund, Inc

Terminated

Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer

Prostate Cancer

United States
Ashutosh Kumar Tewari
Oncovir, Inc.

Completed

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Men Undergoing Radical Prostatectomy

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer

Prostate Cancer

United States
William K. Oh
Prostate Cancer Foundation

Completed

Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca

Prostate Cancer

United States
NYU Langone Health

Completed

Ultrasound Imaging in Finding Prostate Cancer in Patients Undergoing Surgery

Prostate Cancer

United States
Rockefeller University
Memorial Sloan Kettering Cancer Center

Completed

Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer

Prostate Cancer

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection

Prostate Cancer

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404

Prostate Cancer

United States
AstraZeneca

Completed

Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Assessment of the Functional Significance of Accessory Pudendal Arteries

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Completed

MRI/MRSI in Risk Assessment of Prostate Cancer Patients

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
Ambrilia Biopharma, Inc.

Completed

Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

No longer available

Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography

Recurrent Prostate Cancer | Prostate Cancer

United States
Columbia University
Bristol-Myers Squibb; Ferring Pharmaceuticals

Active, not recruiting

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P)

Prostate Cancer

United States
NYU Langone Health

Terminated

Comparative Analysis of Transperineal Versus Transrectal Approaches for MRI-Targeted Biopsy of the Prostate for the Detection and Characterization of Prostate Cancer

Prostate Cancer

United States
NYU Langone Health

Completed

PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy

Prostate Cancer

United States
Weill Medical College of Cornell University

Completed

PSMA Imaging of Localized Prostate Cancer

Prostate Cancer

United States
Weill Medical College of Cornell University

Completed

Neoadjuvant J591 Treatment for Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Modifications to Radical Prostatectomy: Feasibility Study

Prostate Cancer

United States
Beth Israel Medical Center
Bayer

Terminated

Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer

Prostate Cancer

United States
Columbia University
Celgene Corporation

Completed

Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

Withdrawn

Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Radiation Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Rockefeller University

Completed

Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
PSMA Development Corp, LLC

Completed

Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel

Prostate Cancer

United States
Novartis Pharmaceuticals

Completed

Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer

Prostate Cancer

Saudi Arabia, Taiwan, Korea, Republic of, Lebanon, Brazil, China, New Zealand, Australia, Thailand, Kuwait
University of Alabama at Birmingham
Amgen

Completed

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

Metastatic Castration-resistant Prostate Cancer

United States
Novartis Pharmaceuticals

Terminated

Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone

Hormone Refractory Prostate Cancer Disease

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (ASPIRE-PCa)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Spain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
James J. Peters Veterans Affairs Medical Center

Not yet recruiting

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

Metastatic Cancer | Neoplasm, Prostate

United States
National Cancer Institute (NCI)

Completed

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer (TARGET)

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
University of Rochester

Withdrawn

4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy

Prostate Disease

United States
KangLaiTe USA

Terminated

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
Celgene Corporation

Completed

Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer

Prostate Cancer | Castration Resistant Prostate Cancer

United States
University of Rochester

Withdrawn

ConfirmMDx Assay in Multiparametric MRI (mpMRI) PIRADS Scored Lesions After a Negative MR/US Fusion Biopsy

Prostate Disease

United States
Weill Medical College of Cornell University

Completed

PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer (PRAGMA)

Metastatic Prostate Cancer

United States
Dizal Pharmaceuticals

Terminated

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

Metastatic Castration Resistant Prostate Cancer

United States, Korea, Republic of
National Cancer Institute (NCI)

Completed

Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Johnson & Johnson Private Limited

Withdrawn

A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer

Prostate Cancer

India

Clinical Trials on Prostatic Hyperplasia in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations